Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GLTU as well ... in all your stocks.
Friday from 4 to 5 pm, IHub allows us free members the use of many paid member features for free, to try to persuade us of the value of paying. So you can send PMs as well as just receive them from others.
I am usually getting my wife around then and usually forget to get online.
Keith,
None of us are experts on NNAB. There is so little information available anywhere, that any step I take is purely speculation. Consider me the DR XXX of NNAB. And No, I am not a doctor and have no science degree.
Thank you. I use the same modus operandi and sometimes - despite how rational and logical the person may seem - I just shake my head no on some selections.
I periodically go over our portfolio with my financial advisor and he makes me give an elevator pitch why I'm in a stock. Then he sometimes buys the ones I make the best case for.
Many of them are ideas which didn't work out (lol) but they've sunk so low they are also lottery tickets at this point or very long term options. If I need the tax loss, I may sell them.
If you remember at happy hour on friday, why not send me your email and we can talk offline.
And then again, I know nothing. Simple speculation, just like a lottery ticket.
EDIT: seems like you're shadowing me everywhere now!
That sort of thought also occurred to me. However, L&M and CT** and NNAB would be sued up the wazoo by holders of CT**.
It is more realistic - if any of this can be considered realistic - that items Menon had been working on at KARD, but had not completed before spending full time at CT** could be transferred to NNAB. Also, if they do sell CT**, this is the logical place for L&M to "hang out."
Drano, Incoming! Incoming herd of unicorns. There you go.
Just buy more of the shares.
Welcome aboard! Let's hope the next move of pps is up.
Still hopeful we may get something from CERN. Haven't written that possibility off yet.
I'm hesitant to accept any timeline expectation that close. ZMSPF is always sloooowww.
Thank you.
Game, Thanks.
Me three.
Glad you're back.
Would be good if that much cash is coming in. Also would mean acquisition more likely of one of the other companies OPK has a stake in, even though most of their acquisition "currency" is their stock, as it was with Prolor. I doubt anything would happen toward a dividend, but even a token dividend might have a very interesting effect on stock price.
GLTAL
Please post the link. TIA
Whether it is Rayaldee or the 4Score test or something else, it is good to get more folks salivating over OPK and it's products.
Personally, I expect Dr. Frost to fold up at least a couple of the other life sciences companies, in which OPK and he are invested, into OPK and ramp this price up further before he considers his work done here.
Hopefully some explanation of the Ireland deal will be forthcoming.
Yes OPKO-Ireland was out of the blue. Me thinketh more is afoot, between OPKO and Pfizer.
The particular drug may be lesser-known, but the platform used to extend the bioactive life of the compounds for HGH and hemophilia has almost unlimited application. That was the best part of Porlor and while Frost had OPK buy his shares along with ours.
Thank you George.
Just sitting waiting here. Much more excitement in our other stocks in common.
I suspect Karin doesn't care so much about page views as a method of remuneration. However, someone with lots of "clicks" may have an easier job of getting their articles published. Just my speculation.
Repost from CT** board about NNAB:
I Need Help Thursday, 01/29/15 04:03:01 PM
Re: None
Post # of 89789
CTIX getting good press.
Thank you Karin. You penned another excellent article for the SA space. You are one of the principal reasons I originally took interest in CTIX. Thank you.
Ellaruth made mention of a favorable article published in Barron's by Robin Goldwyn Blumenthal. From Ellaruth's Blog (on SA):
Quote:Barron's Article By Robin Goldwyn Blumenthal On Cellceutix & Nanoantibiotics 0 comments
Jan 29, 2015 2:20 PM | about stocks: CTIX, NNAB, CELG, AAPL, MRK
Wall St Nightingale Whispers In The Night
Barron's columnist Robin Goldwyn Blumenthal, had her attention drawn to two racy pink sheet stocks named Nanoantiobiotics,(OTCPNKS:NNAB) as well as Cellceutix (OTCPNKS:CTIX). As she reviewed both companies, I am sure that she applied the infamous critical apparatus that Barron's columnists have been known for. I surmise that she read of the multi-billion dollar mega-blockbuster expectancy of many of Cellceutix shareholder's. Oftentimes when a pink sheet stock is mentioned by a Barron's Columnist it becomes the prelude to an eloquent corporate eulogy. However, it is the public relations dream come true for a bulletin board or pink sheets company to receive positive public relations from a Barron's Columnist. In this case it happened not to one, but to two distinct biotechnology companies. The link between the two companies is that Cellceutix, two primary principals CEO,CFO Leo Ehrlic and President and CSO Dr. Krishna Menon are the fathers of the two primary principals of Nanoantibiotics CEO, CFO Elliot Ehrlic, and President Rajah Menon. Like father's, like son's. Of note, is the fact that she withheld comment on the stratospheric expectancies of Cellceutix common shareholders.
An Intriguing Pink Sheet Discovery
How did Ms Blumenthal discover the two companies? Was it painstaking research into finding the next Genentech or Celgene (NASDAQ:CELG)? If so, I think that she has been successful so far as Cellceutix is concerned. Did a motivated cartel of shorts or longs obtain her attention? Did she decided to make a positive paternal spin, as over winsomely discussing the merits of Cellceutix or Nanoantiobiotics, which could have required her to fill out a dissertation of compliance forms and defensive memo's. Indeed she would suffer less regulatory problems if she had recommended that Ms Jeremiah Wright sell her Obama phone and buy State of Maryland lottery tickets. Better yet it could have been that recent shorts conspired to obtain a Barron's corroboration with their Grinch type fallacies of Cellceutix, only to be sorely disappointed.
I ask "Where Is The Giant Sucking Sound" ? The Shorts?
I for one would like for the Cellceutix shorts to state their positions and pledge to remain short until December 26th, 2016 so that I can have their financial family jewels in my Christmas stockings for the next two consecutive years. Pssst calling Bill Ackerman or Carl Icahn, ignorant gonads for sale amongst CTIX shorts. Their misplaced bets have created a significant vortex. How? By simply failing to read the articles hyperlinked and linked in this article. Instead of Victoria's Secret, we shall label the links as Blumenthal's Secrets.
The Latent Antibiotic Supercharger
Embedded within Ms Blumenthal's coverage of the two companies, two fathers and two sons is an valuable latent possibility. Despite Brilacidin's excellent FDA 2b results in displaying superior performance to Merck/Cubist's (NYSE:MRK) Daptomycin, some scientists have purported that Definsin Mimetics are just another new class of antibiotics and eventually be opposed by the resistance that bacteria will develop to them, just like all other types of antibiotics. I find the logic of the prior statement in need of an intellectual handicap sign. However, it does not require a Disney imagination to see that (IF?) you were able to develop a technology to seriously damage or completely disable the efflux pump in bacteria, combining could provide them with an astounding new blockbuster status. Imagine what such a technology would do in combination with Brilacidin! Succinctly, the two sons are a backstop and perhaps a huge expansion of the definsin antibiotic franchise. It could result in many generic antibiotics being supercharged.
Ms. Blumenthal is to be commended for restraint in not forcefully recommending highly speculative pink sheet stocks, while having the clairvoyance to elegantly suggest that something novel might be happening in Cellceutix, and also Nanoantibiotics. In reference to both Brilacidin and Kevetrin, the phenomenal has already occurred and her apparent reverence bespeaks that more scientific progress could result in bolder, broader expository coverage. The Cellceutix shorts have only a little time between two technical camel humps before they find themselves on the tip of a Rhinoceros horn. The shofar will blow in Zion, after the FDA 1 results with regard to Kevetrin come in, combined with other trial progress.
Coretta Scott King & Ovarian Cancer
Immediately after Martin Luther King Jr. Day, and on the cusp of African American history month, its important to note that Mrs Coretta Scott King, died while battling Ovarian Cancer. How could any woman have less than hope when looking at Kevetrin's Ovarian/Spleen Results from its recent cohort in FDA 1.
seekingalpha.com/news/2230606-cellceutix-up-on-report-of-positive-results-in-clinical-trial
I Had A Dream Deeply Rooted In The Cellceutix Dream
By the way I saw Steve Job's yesterday and he implied to me that if he could have found a P53 activating drug (NASDAQ:APPL) like Kevetrin in 2009, that he believe that he would still be the CEO of Apple. Shortly thereafter I heard Coretta Scott Kings voice say that had she had Kevetrin, she believes that she would have been able to buy a ticket to watch the movie Selma. Do not worry, I am not hallucinating, you understand that myth has a kernel of truth. In this one the kernel is quite large.
Combining the above with the Daptomycin trial results and the FDA's QIDP designation is enough to provide any long with reasonable time event expectancy for multiplication of capital.
Let Journalistic Justice Roll Down Like Waters And Scientific Progress Like A Mighty Stream
Robin Goldwyn Blumenthal, and Barron's certainly deserve to be recognized by the Cellceutix shareholder family. It's time for New York Times writer Gina Kolata, and Andrew Baum, at Citicorp to demonstrate that they have eagle like clairvoyance, as over chicken like myopia. Has any other drug in the P53 race produced the safety and or efficacy results thus far that Cellceutix has? Short the New York Times and buy Barron's.
Themes: Barron's, Antibiotics, Nanotechnology, Chemotherapy, Cancer, Oncology Stocks: CTIX, NNAB, CELG, AAPL, MRK
I would guess the 12k was an order someone had sitting there as good-till-cancelled. Someone wanted to buy 12k NNAB lottery tickets. Someone else put in a sell order. Boom, match made in heaven.
There certainly is no great amount of public information, only the recent Barrons article.
Yup, still here and holding a minor position
If you expand the details it says:
The principal author of the Declaration of Independence and one of the most illustrious founding fathers, Thomas Jefferson was elected the third President of the United States in 1800. During his tenure as President, Jefferson authorized the purchase of the Louisiana Territory, dispatched Lewis and Clark westward in order to explore the remainder of the continent and repealed the Whisky Excise Tax.
After Jefferson retired from public office in 1815, he often tended to the garden that he had cultivated at his Monticello estate. At the time, it was customary for wealthy farmers, including Jefferson, to make their own garden spirits. Each farmer's spirits were unique and reflected their personal tastes and the local terroir of their farm. Jefferson's Reserve Very Old Straight Bourbon Whiskey is crafted by Chet and Trey Zoeller in honor of Jefferson and his experimental nature. While the Zoellers were inspired by Jefferson, their own roots can be traced back for generations deep into Kentucky's bourbon history.
Jefferson's Reserve Very Old Bourbon is a complex blend of three unique bourbons - each made from a mash of corn, rye and malted barley - that are aged for up to twenty years and brought to proof with Kentucky limestone water. While most small batch bourbons are made from a blend of 200 to 300 different casks, each batch of Jefferson's Reserve is crafted from only 8 to 12 casks, causing the Zoellers to label their bottling process as "ridiculously small batch." The difference, Zoeller says, is like "making dinner for eight guests instead of eighty. You are able to deliver a great product that has the nuances you are striving for."
Like Jefferson himself, Jefferson's Reserve Bourbon is complex, elegant and sophisticated. It has an aroma of gentle, creamy vanilla, soft spices and dried fruits that open up to notes of toffee, roasted corn and tobacco, before leading to a lingering, dry finish. Jefferson's Reserve earned a score of 94 points from the Beverage Testing Institute and the Gold Medal at the San Francisco World Spirits Competition.
"Jefferson's is a handmade product that I put my name on, which makes it hugely important," says Zoeller. Try a handmade whiskey today!
Caskers advertising Jefferson's Reserve by email:
"Jefferson's Reserve Very Old Straight Bourbon Whiskey
Made in homage to Thomas Jefferson, this bourbon earned a score of 94 points from the Beverage Testing Institute.
$59.99" marked down from $64.99
https://www.caskers.com/jefferson-s-reserve-very-old-straight-bourbon-whiskey-1708/
That was my conclusion as well. He works for Seeking Alpha.
I can't imagine he would have enough money on his own, other than possibly from his family, that he would be having any substantial short position. You have to have marginable securities.
Make it a glass of Jefferson's Ocean Bourbon and I'll join you.
So, magically, one of my earlier comments - edited poorly and an insult to my grammar - has reappeared on SA.
Some of our comments as a group may have impugned the ability of this kid to write, and I can see how they might delete those as a "personal attack." However, many of those comments are still up there, while the key post by Karin has been deleted. I wish I could cut and paste (I have a pdf) but I can't.
My comments deleted a second time. They probably will delete my third attempt at comments.
He specifically noted he was short, ahead of the "article" itself.
Yup. Hoping Karin can put this punk's specious argument to rest.
And I just added his LinkedIn page, with the sole reference being his supervisor at Seeking Alpha. I'm sure that will be deleted soon, as well.
Wild,
You still have a comment there. Mine, and more importantly Karin's more detailed response, were removed.
Steve
Interesting that he cites only the one job. Also interesting that the one recommendation also says: "October 23, 2014, Jack managed Christopher at Seeking Alpha"
So it appears that the kid has only worked FOR Seeking Alpha, yet he is putting out hit pieces. No wonder he got this laughable piece published.
Bought a few more today. Couldn't resist.
Business Week article on how Ken Moch saved Josh Hardy's life but lost his job.
http://www.businessweek.com/articles/2015-01-22/biotech-drug-approvals-social-media-storm-hits-chimerix?campaign_id=yhoo
Yes, article was interesting and very balanced for that site. Clearly we retail shareholders are just along for the ride on this one.